{"resourceType": "Evidence", "meta": {"versionId": "7", "lastUpdated": "2024-12-13T21:07:33.593Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"]}, "title": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ComparativeParticipantFlowEvidence", "display": "ComparativeParticipantFlowEvidence"}]}}], "status": "active", "url": "https://fevir.net/resources/Evidence/179635", "id": "179635", "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/179635", "assigner": {"display": "Computable Publishing LLC"}}], "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "author": [{"name": "Brian S. Alper"}], "description": "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial", "relatedArtifact": [{"type": "cite-as", "citation": "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json."}, {"type": "derived-from", "resourceReference": {"reference": "Citation/179637", "type": "Citation", "display": "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"}}], "variableDefinition": [{"description": "Participants in the opioid detoxification trial", "variableRole": "population"}, {"description": "GroupAssignment: Lofexidine vs. Placebo", "variableRole": "exposure", "comparatorCategory": "false"}, {"description": "Dropout due to stopping intervention", "variableRole": "outcome", "observed": {"reference": "EvidenceVariable/179636", "type": "EvidenceVariable", "display": "PartiicipantFlowMeasure: Dropout due to stopping intervention"}}], "statistic": [{"description": "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)", "statisticType": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000245", "display": "Risk Ratio"}]}, "quantity": {"value": 1.59}, "numberAffected": 30, "sampleSize": {"numberOfParticipants": 68}, "attributeEstimate": [{"description": "p < 0.01", "type": {"coding": [{"system": "https://fevir.net/sevco", "code": "STATO:0000700", "display": "p-value"}]}, "quantity": {"comparator": "<", "value": 0.01}}]}], "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}, "name": "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial"}